LBP-EC01

DRUG2 trials

Sponsors

Locus Biosciences

Conditions

Urinary Tract Infections

Phase 1

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

CompletedNCT04191148

Locus BiosciencesUrinary Tract Infections

Start: 2019-12-30End: 2020-11-19Updated: 2022-03-16

Phase 2

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

RecruitingNCT05488340

Locus BiosciencesUrinary Tract Infections

Start: 2022-07-13End: 2027-12-01Target: 318Updated: 2026-09-14

Related Papers

Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.

2024-08-0939 citations